UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000016637
Receipt No. R000019284
Scientific Title Study of the improvement effect of potassium competitive acid blocker and proton pump inhibitors on symptoms in patients with reflux esophagitis (RE): a randomized comparative study of vonoprazan 20mg vs. rabeprazole 10mg using the time (number of days) to improvement in symptoms as an index
Date of disclosure of the study information 2015/02/26
Last modified on 2017/02/27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Study of the improvement effect of potassium competitive acid blocker and proton pump inhibitors on symptoms in patients with reflux esophagitis (RE): a randomized comparative study of vonoprazan 20mg vs. rabeprazole 10mg using the time (number of days) to improvement in symptoms as an index
Acronym Study of the improvement effect of potassium competitive acid blocker and proton pump inhibitors on symptoms in patients with reflux esophagitis (RE): a randomized comparative study of vonoprazan 20mg vs. rabeprazole 10mg
Scientific Title Study of the improvement effect of potassium competitive acid blocker and proton pump inhibitors on symptoms in patients with reflux esophagitis (RE): a randomized comparative study of vonoprazan 20mg vs. rabeprazole 10mg using the time (number of days) to improvement in symptoms as an index
Scientific Title:Acronym Study of the improvement effect of potassium competitive acid blocker and proton pump inhibitors on symptoms in patients with reflux esophagitis (RE): a randomized comparative study of vonoprazan 20mg vs. rabeprazole 10mg
Region
Japan

Condition
Condition patients with reflux esophagitis
Classification by specialty
Gastroenterology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To compare the clinical effect of vonoprazan 20mg/day vs. rabeprazole 10mg/day after 1 week of treatment in patients with reflux esophagitis using the time (number of days) to improvement in reflux symptoms as an index
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Time (number of days) to improvement in reflux symptoms after 1 week of treatment
Key secondary outcomes i Change in reflux symptom score after treatment
ii. Improvement rates in reflux symptoms after 2 and 4 weeks of treatment
iii. Frequency of heartburn, acid regurgitation (sensation of gastric acid reflux), stomach pain, heavy stomach feeling, early satiety, nausea, burping, and bloating in subjects prior to treatment assignment
iv. Improvement rate in individual symptoms after 2 and 4 weeks of treatment
v. Improvement rate in overall symptoms after 2 and 4 weeks of treatment
vi. Factors such as patient background and morbidity period which affect change in score after treatment

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Vonoprazan (Takecab) 20mg orally once a day in the morning
Interventions/Control_2 Rabeprazole (Pariet) 10mg orally once a day in the morning
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria (1) Patients who have freely given written consent to participating in the study after receiving a full explanation (written and oral) of the study.
(2) Patients of either sex who are at least 20 years of age.
(3) Patients diagnosed endoscopically in the past 12 months with Grade A-D (Los Angeles classification) reflux esophagitis
(4) Patients with a Global Overall Severity (GOS) score of 4 (troublesome to a moderate degree) for heartburn and/or acid regurgitation (sensation of gastric acid reflux) in the Epigastric Symptom Questionnaire
Key exclusion criteria (1)Patients with a history of gastrointestinal resection or vagotomy
(2)Patients with warning signs such as vomiting, gastrointestinal bleeding (including findings of hematemesis, melena, and anemia), and sudden weight loss
(3)Patients with peptic ulcer (except those in scarring stage)
(4)Patients with a history of, or who currently have, any of the following diseases:
Zollinger-Ellison syndrome
Inflammatory Bowel Disease (IBD)
Irritable Bowel Syndrome (IBS)
Esophageal stricture
Esophageal achalasia
Malabsorption
Cerebrovascular disorders such as cerebral hemorrhage and cerebral infarction
(5)Patients whose participation in this study would be contraindicated due to complications such as serious hepatic disease, renal disease, or cardiac disease.
(6)Patients with a confirmed, or suspected, malignant lesion
(7)Women who are pregnant or who may possibly be pregnant, and lactating mothers
(8)Patients who require continued treatment with drugs (atazanavir sulfate, diazepam, phenytoin, warfarin, tacrolimus hydrate, digoxin, methyldigoxin, itraconazole, gefitinib, voriconazole, and antacids containing aluminium hydroxide gel and magnesium hydroxide) which may interact with the study drugs
(9)Patients receiving treatment with proton pump inhibitors, H2-receptor antagonists, prokinetic agents, gastric mucosa protective agents, anticholinergics, antacids, antidepressants, antianxiety
agents, antidiabetic drugs, steroids (excluding external preparations), non-steroid anti-inflammatory drugs (NSAIDs), aspirin preparations including low-dose aspirin and/or bisphosphonate drugs. However, patients who discontinue using these drugs for at least 1 week prior to the symptom survey or switch to another treatment, may enrol in the study.
(10)Other patients whom the investigator considers unsuitable for admission to the study
Target sample size 100

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Daisuke Asaoka
Organization Juntendo University School of Medicine, Tokyo, Japan
Division name Department of Gastroenterology
Zip code
Address 2-1-1, Hongo, Bunkyo-ku, Tokyo, Japan
TEL +81338133111
Email daisuke@juntendo.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Daisuke Asaoka
Organization Juntendo University School of Medicine, Tokyo, Japan
Division name Department of Gastroenterology
Zip code
Address 2-1-1, Hongo, Bunkyo-ku, Tokyo, Japan
TEL +81338133111
Homepage URL
Email daisuke@juntendo.ac.jp

Sponsor
Institute Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 02 Month 26 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2015 Year 02 Month 20 Day
Date of IRB
Anticipated trial start date
2015 Year 02 Month 26 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2015 Year 02 Month 25 Day
Last modified on
2017 Year 02 Month 27 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019284

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.